In 88% of ALL an hyperactivation of the PI3K/AKT/MTOR signaling pathway is reported and this activation is associated with poor prognosis and chemotherapeutic resistance [20, 21]. The gene discussed is AKT1; the disease is acute lymphoblastic leukemia.